周五，生命科学工具公司Avantor Inc（纽约证券交易所代码：AVTR）报告第四季度净销售额为16.9亿美元，同比下降2%，低于市场预期的17.1亿美元。 外币换算和临床服务业务剥离产生了负面影响，导致有机销售增长仅为1%。 公司净收入从去年的9850万美元增加到5.004亿美元，调整后的净收入为1.839亿美元，而去年同期为1.667亿美元。 公司报告调整后的息税折旧及摊销前利润（EBITDA）为3.077亿美元，利润率为18.2%。调整后的营业收入为2.794亿美元，利润率为16.6%。 公司报告调整后的每股收益（EPS）为0.27美元，较去年的0.29美元有所下降，但超出市场预期的0.26美元。 经营现金流为1.733亿美元，自由现金流为2.221亿美元。 Avantor总裁兼首席执行官Michael Stubblefield表示：“正如预期的那样，我们在第四季度恢复了增长，调整后的EBITDA利润率、调整后的EPS和自由现金流转换率同比和环比均实现了增长。我们生物处理平台实现了高个位数的增长，预计在我们集中执行力和改善的最终市场条件的推动下，继续保持强劲增长。” 实验室解决方案的净销售额为11.3亿美元，下降5%。外币换算和临床服务业务剥离产生了负面影响，导致有机销售额下降1%。 生物科学生产净销售额为5.608亿美元，增长4%。有机销售增长4%。 前景展望：Avantor预计2025年有机营收增长为1%-3%，而2024年则预计下降2%，调整后的EBITDA利润率为18%-19%。 公司预测调整后的每股收益在1.02美元至1.10美元之间，而市场预期为1.10美元，预计自由现金流为6.5亿美元至7亿美元。 股价走势：截至周五盘前交易时段，AVTR股票下跌3.73%，报20.89美元。

以上内容来自Benzinga Earnings专栏，原文如下：

On Friday, Avantor Inc (NYSE:AVTR) reported fourth-quarter net sales of $1.69 billion, a decrease of 2% year-over-year, missing the consensus of $1.71 billion.

Foreign currency translation and Clinical Services divestiture had a negative impact, resulting in sales growth of 1% on an organic basis.

Net income increased to $500.4 million from $98.5 million a year ago, and adjusted net income was $183.9 million compared to $166.7 million in the comparable prior period.

Also Read: Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis

The life science tools company reported the adjusted EBITDA was $307.7 million, and the margin was 18.2%. Adjusted operating income was $279.4, with a margin of 16.6%.

The company reported an adjusted EPS of 27 cents, up from 29 cents a year ago, beating the consensus of 26 cents.

Operating cash flow was $173.3 million, while free cash flow was $222.1 million.

“As anticipated, we returned to growth in the fourth quarter and delivered sequential and year-over-year growth in adjusted EBITDA margin, adjusted EPS, and best-in-class free cash flow conversion. We grew our bioprocessing platform high-single-digits and expect continued strength driven by our focused execution and improving end market conditions,” said Michael Stubblefield, President and Chief Executive Officer.

Laboratory Solutions’ net sales were $1.13 billion, down 5%. Foreign currency translation and our Clinical Services divestiture had a negative impact, resulting in a 1% organic sales decline.

Bioscience Production net sales were $560.8 million, up 4%. Sales increased 4% organically.

Guidance: Avantor expects 2025 organic revenue growth of 1%-3% compared to 2024 decline of 2%, with adjusted EBITDA margin of 18%-19%

The company forecasts adjusted EPS of $1.02-$1.10 versus the consensus of $1.10 and expected free cash flow of $650 million—$700 million.

Price Action: AVTR stock is down 3.73% at $20.89 during the premarket session on last check Friday.

Read Next:

• Wynn’s Al Marjan Island Resort Expansion Gains Momentum, Secures Financing